Tradegate
19.01.26 | 18:13
4,120 Euro
-1,90 % -0,080
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,360 | 4,520 | 23:01 | |
| 4,340 | 4,520 | 22:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | Silence Therapeutics beruft CFO Rhonda Hellums in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| SILENCE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.12.25 | Silence Therapeutics plc - 8-K, Current Report | 1 | SEC Filings | ||
| 15.12.25 | Silence Therapeutics Announces Leadership Changes | 1 | City A.M. | ||
| 15.12.25 | Silence Therapeutics CEO Craig Tooman steps down | 1 | Investing.com | ||
| 15.12.25 | Silence Therapeutics CEO Tooman to depart; Chairman Ross to lead on interim basis | 4 | Seeking Alpha | ||
| 12.11.25 | Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 6 | City A.M. | ||
| 12.11.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference | 349 | Business Wire | Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in a fireside chat... ► Artikel lesen | |
| 06.11.25 | Silence Therapeutics: EPS übertrifft Schätzungen um 0,04 $ - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| 06.11.25 | Silence Therapeutics plc Non-GAAP EPS of -$0.15, revenue of $0.16M | 2 | Seeking Alpha | ||
| 06.11.25 | Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 4 | City A.M. | ||
| 06.11.25 | Silence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights | 434 | Business Wire | SANRECO Phase 2 study of divesiran in polycythemia vera (PV) fully enrolled; topline results anticipated in 3Q 2026 Strong balance sheet and cash runway into 2028
Silence Therapeutics plc, Nasdaq:... ► Artikel lesen | |
| 06.11.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.11.25 | Silence Therapeutics plc - 8-K, Current Report | 2 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics plc - 8-K, Current Report | 5 | SEC Filings | ||
| 23.10.25 | Silence Therapeutics completes enrollment in PV treatment study | 3 | Investing.com | ||
| 23.10.25 | Silence Therapeutics plc: Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) | 349 | Business Wire | Rapid Completion of Phase 2 Enrollment Reflects Ongoing Momentum for Divesiran as First-in-Class siRNA for PV Topline Results Anticipated in 3Q'26
Silence Therapeutics plc (Nasdaq: SLN), a global... ► Artikel lesen | |
| 02.09.25 | Silence Therapeutics plc: Silence Therapeutics to Participate in September Investor Conferences | 438 | Business Wire | Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate... ► Artikel lesen | |
| 07.08.25 | Silence Therapeutics plc - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 07.08.25 | Silence Therapeutics plc: Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 403 | Business Wire | Presented Updated SANRECO Phase 1 Data at EHA 2025 Further Supporting Potential for Divesiran as First-in-Class siRNA in PV
SANRECO Phase 2 Study On-Track for Complete Enrollment by Year-End 2025
Silence... ► Artikel lesen | |
| 07.08.25 | Silence Therapeutics plc - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 51,86 | +2,63 % | Novo-Nordisk-Aktie vor Kaufsignal: Darauf kommt es jetzt an! | Die Anteile des dänischen Pharmakonzerns sind vielversprechend in das neue Börsenjahr gestartet, doch jetzt wartet eine echte charttechnische Herausforderung. Novo Nordisk: Starker Start ins neue Jahr... ► Artikel lesen | |
| GILEAD SCIENCES | 106,58 | +0,97 % | GILEAD SCIENCES INC CDR - Ruhe als strategisches Signal | ||
| VERTEX PHARMACEUTICALS | 376,60 | -0,49 % | JPM26: Vertex hopes to match cystic fibrosis success in pain and kidney disease | ||
| INNOCAN PHARMA | 4,500 | -9,64 % | INNOCAN PHARMA CORPORATION: Strukturelle Ruhe, klare Linie | ||
| IONIS PHARMACEUTICALS | 64,60 | -2,21 % | JPM26: Tryngolza set to become first wholly owned Ionis blockbuster | ||
| SNDL | 1,354 | -3,01 % | 1CM Inc.: SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan | Edmonton, Alberta and Toronto, Ontario--(Newsfile Corp. - January 7, 2026) - SNDL Inc. (NASDAQ: SNDL) (CSE: SNDL) ("SNDL") and 1CM Inc. (CSE: EPIC) (OTCQB: MILFF) (FSE: IQ70) ("1CM") are pleased... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 23,000 | -9,80 % | Gilead Exercises Option To License Assembly Bio's Helicase-Primase Inhibitor Programs | FOSTER CITY (dpa-AFX) - Gilead Sciences (GILD) and Assembly Biosciences (ASMB) announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus helicase-primase... ► Artikel lesen | |
| HAPPY BELLY FOOD GROUP | 1,140 | -2,56 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Announces Multi-Unit Franchisee Signs on to Open Their 6th GTA Location at Bloor & Spadina in Toronto | Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| ALNYLAM PHARMACEUTICALS | 300,00 | -1,99 % | Alnylam Pharmaceuticals stock price target lowered to $465 at RBC Capital | ||
| LIGAND PHARMACEUTICALS | 157,00 | -1,26 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| PROMINO NUTRITIONAL SCIENCES | 0,015 | 0,00 % | Promino Nutritional Sciences Inc (2): Promino Nutritional increases financing to $1.72M | ||
| WAVE LIFE SCIENCES | 11,300 | -1,74 % | Neuer Geheimtipp aus der Biotech-Szene - Wave Life Sciences hat sich zu Wochenbeginn mehr als verdoppelt! | Ist ein neuer Abnehm-Star geboren? Wave Life Sciences könnte mit einem bisher einzigartigen Wirkstoff den Adipositas-Markt aufmischen. Ein Ansatz, der Fett abbaut, Muskeln erhält und die Konkurrenz... ► Artikel lesen | |
| DARE BIOSCIENCE | 1,930 | 0,00 % | Daré Bioscience, Inc.: Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update | DARE to PLAY Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued... ► Artikel lesen | |
| HYTN INNOVATIONS | 0,127 | 0,00 % | HYTN begrüßt US-Präsidialverordnung zur Einstufung von Cannabis in Schedule III | Vancouver, British Columbia - 18. Dezember 2025 / IRW-Press / HYTN Innovations Inc. (CSE: HYTN, FWB: 85W0, OTC PINK: HYTNF) ("HYTN" oder das "Unternehmen"), ein
Hersteller von Cannabis in pharmazeutischer... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 0,600 | -7,69 % | TuHURA Biosciences, Inc.: TuHURA Biosciences Provides Corporate Update Following Recent Financing | Company's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma... ► Artikel lesen |
SILENCE THERAPEUTICS PLC ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -1,90 % bei einem Aktienkurs von 4,120 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILENCE THERAPEUTICS PLC ADR finden Sie auf Wallstreet Online.